In celebration of November’s Native American Heritage Month and Stomach Cancer Awareness Month observances, the John Wayne Cancer Foundation is funding research that will allow doctors to assess barriers to treatment of H. pylori and disseminate findings to community health partners to reduce the occurrence of stomach cancer.
FDA has approved Vyloy (zolbetuximab-clzb), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
